Bronkese 169.4mg/50.6mg Injection
Marketer
Tribhawan Injectables
Salt Composition
Etofylline (169.4mg) + Theophylline (50.6mg)
Overview Bronkese 169.4mg/50.6mg Injection
Asthman and chronic obstructive pulmonary disease (COPD), a lung condition restricting airflow, are treated with a single injection of Respiflow (169.4mg/50.6mg). This medication eases breathing by relaxing airway muscles. Administered by a healthcare professional, the dosage is individualized based on your health and response. Continue treatment as directed; premature discontinuation may lead to symptom recurrence and condition worsening. Inform your doctor of all other medications you are taking, as interactions are possible. Common, usually temporary, side effects include nausea, vomiting, indigestion, headache, and anxiety. Report any concerning side effects immediately. Before treatment, disclose any heart, kidney, or liver conditions to ensure appropriate dosage. Also, inform your doctor of pregnancy, pregnancy plans, or breastfeeding.
Uses of Bronkese 169.4mg/50.6mg Injection
Managing chronic obstructive pulmonary disease (COPD)
Major Benefits of Bronkese 169.4mg/50.6mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Bronkese 169.4mg/50.6mg Injection:
- Nausea
- Vomiting
- Headache
- Restlessness
How to use Bronkese 169.4mg/50.6mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
How Bronkese 169.4mg/50.6mg Injection works:
Etofylline and theophylline, combined as Bronkese Injection (169.4mg/50.6mg), act as bronchodilators. Their mechanism involves airway muscle relaxation, leading to wider airways and improved breathing.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of alcohol and Bronkese 169.4mg/50.6mg Injection poses a safety risk.
PregnancyCONSULT YOUR DOCTOR
The use of Bronkese 169.4mg/50.6mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to any prescription. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Administering Bronkese 169.4mg/50.6mg Injection during lactation presents minimal risk. Research in humans indicates negligible transfer of the medication into breast milk, posing no apparent harm to the infant. Post-injection, a 2-4 hour period of abstaining from breastfeeding may further reduce infant exposure to the drug.
DrivingCONSULT YOUR DOCTOR
The effect of Bronkese 169.4mg/50.6mg Injection on driving ability is unknown. Refrain from operating a vehicle if experiencing symptoms impairing concentration or reaction time.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Bronkese 169.4mg/50.6mg Injection to individuals with renal impairment. Physician consultation is advised.
LiverCAUTION
Individuals with hepatic impairment should use the 169.4mg/50.6mg Bronkese Injection with care. Dosage modification of this injection may be necessary. Physician consultation is recommended.
What if you forget to take Bronkese 169.4mg/50.6mg Injection :
Omit a Bronkese 169.4mg/50.6mg Injection dose? Seek your physician's advice.
Facts to Know About Bronkese 169.4mg/50.6mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Breathing |
3,018 People bought this recently